Also known as: thalidomide analogue
Lenalidomide is an oral immunomodulatory imide drug (IMiD), also described as a cereblon E3 ligase modulator, used in hematologic malignancies such as multiple myeloma and selected lymphomas/MDS. It is marketed under the brand name Revlimid. U.S. approval was first granted in 2005.
An interim phase 3 analysis showed mezigdomide plus carfilzomib and dexamethasone reduced the risk of progression or death in relapsed/refractory multiple myeloma. The SUCCESSOR-2 study remains ongoing and will assess overall survival and safety.
New data from the American Cancer Society shows the U.S. cancer death rate has dropped 34% since 1991, preventing nearly five million deaths. More than 18 million Americans are living after a cancer diagnosis, with that number expected to surpass 22 million by 2030.
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
Researchers have engineered immune cells to sense cancer metabolites, improving tumor infiltration in solid cancers. Separate studies identify Kappa and Lambda Myeloma Antigens as specific targets for multiple myeloma treatment, while mRNA-based personalized cancer vaccines show promise through AI-driven neoantigen selection.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
MajesTEC-9 trial demonstrates teclistamab's superiority over standard care in second-line multiple myeloma treatment, with significant progression-free survival and overall survival benefits supporting earlier use of the BCMA-targeting bispecific antibody.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594899 |
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL |
NOT_YET_RECRUITING | PHASE2 |
| NCT07585747 |
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide |
NOT_YET_RECRUITING | PHASE2 |
| NCT07562022 |
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07560449 |
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms |
NOT_YET_RECRUITING | PHASE2 |
| NCT07485647 |
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing |
NOT_YET_RECRUITING | PHASE2 |
| NCT07465029 |
A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain |
ACTIVE_NOT_RECRUITING | |
| NCT07460362 |
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma |
RECRUITING | PHASE2 |
| NCT07448324 |
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL |
RECRUITING | PHASE2 |
| NCT07428369 |
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07384624 |
Combining Latency Reversing Agents to Address the HIV Reservoir |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
